Skye Bioscience, Inc.
SKYE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001516551
In the last 90 days, Skye Bioscience, Inc. insiders filed 0 open-market purchases and 3 sales; 42 institutions reported holding it in 13F filings for Q2 2026, worth $11.1M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Skye Bioscience, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 62 | 3 | 74 | +15 |
| Shares | 24.5M | 1.80M | 25.7M | +3.03M (+13.4%) |
| Value | $196.3M | $14.4M | $100.6M | −$81.2M (−44.7%) |
3 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (22)
Institutions that held Skye Bioscience, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (7)
Institutions that held Skye Bioscience, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Janus Henderson Group PLC | 905,650 | $7.29M |
| Perceptive Advisors LLC | 500,000 | $4.00M |
| Alpine Global Management, LLC | 16,807 | $134.6K |
| MetLife Investment Management | 4,796 | $38.4K |
| Dunhill Financial, LLC | 50 | $401 |
| Asset Dedication, LLC | 16 | $129 |
| CoreCap Advisors, LLC | 8 | $64 |
Not filed for Q3 2024 yet (3)
Institutions that held Skye Bioscience, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 1,118,767 | $8.96M |
| CVI Holdings, LLC | 679,739 | $5.44M |
| Sofos Investments, Inc. | 1,600 | $12.8K |